

KSMO

2019

12th Annual Meeting of
Korean Society of Medical Oncology &
2019 International Conference

Nov. 7 (Thu) - 8 (Fri), 2019
Dragon City Hotel, Seoul, Korea



ALL ABOUT MEDICAL ONCOLOGY

From 100 World Renowned Speakers

PRESIDENTIAL SYMPOSIUM

THE VHL TUMOR SUPPRESSOR GENE:
INSIGHTS INTO OXYGEN SENSING AND CANCER

William G. KAELIN, Jr.
Dana-Farber Cancer Institute, USA



PLENARY 1

TARGETING DNA REPAIR IN BREAST
CANCER

Andrew Tutt (The Institute of Cancer Research, UK)



PLENARY 2

PAST, PRESENT AND FUTURE OF
GERIATRIC ONCOLOGY

Hans Wildiers (University Hospitals Leuven, Belgium)



PLENARY 3

THE REALITY VERSUS POTENTIAL OF
IMMUNE CHECK-POINT INHIBITORS AS
CANCER THERAPEUTICS

Heather A. Wakelee (Stanford University, USA)

HIGHLIGHTS
OF
KSMO 2019



1,000
Attendees



450
Presentations



30
Countries



47
Exhibition Booths

Pre-Registration Deadline: Oct. 18 (Fri)

Category	Pre-registration	On-site Registration
Physician / Fellow		
Member	\$ 100	\$ 120
Non-member	\$ 120	\$ 150
Resident / Nurse / Pharmacist / Technician / Student		
* Related Society Member		
Member	\$ 50	\$ 70
Non-member	\$ 70	\$ 90
Industry		
Member	\$ 100	\$ 120
Non-member	\$ 140	\$ 170

* Related Societies

- ASCO: American Society of Clinical Oncology
- JSMO: Japanese Society of Medical Oncology
- KOSRO: Korean Society for Radiation Oncology
- KCSG: Korean Cancer Study Group
- KSGO: The Korean Society of Gynecologic Oncology
- KOGO: KOREA Genome Organization
- KSP: The Korean Society of Pathologists
- KSR: The Korean Society of Radiology
- KSSO: The Korean Society of Surgical Oncology
- KONS: Korean Oncology Nursing Society
- KSHF: The Korean Society of Health-System Pharmacists

PROGRAM AT A GLANCE

Date	November 7 (Thu)							November 8 (Fri)					
Room	HANRA 1	HANRA 2	HANRA 3	BAEKDU 1	BAEKDU 2	BAEKDU 3	BAEKJE	Lobby	BAEKDU 1	BAEKDU 2	BAEKDU 3	BAEKJE	Lobby
08:00									SL 7 Eisai Korea Inc. & IPSEN KOREA: Hepatocellular Carcinoma	SL 8 Merck Ltd. Korea: Rare Cancer	SL 9 Amgen Korea: Bone Health	SL 10 Takeda Korea: NSCLC	
09:00	Opening Ceremony								SS 8 Partnering between biotechs and investigators in early phase drug development	SS 9 Precision oncology and cancer epigenetics	JS 4 Multidisciplinary efforts for awareness and minimizing toxicities from systemic cancer therapy	OP 4	
10:00	SS 1 Current status of precision medicine in oncology area	SS 2 IT Biotech & digital health in oncology	SS 3 Emerging strategies in immunotherapy	SS 4 State of the art on systemic therapy in HCC					Break				
11:00	PL 1	● Targeting DNA repair in Breast Cancer (Andrew Tutt)							Break				
	Presidential Sym.	● The VHL tumor suppressor gene: Insights into oxygen sensing and cancer (William G. Kaelin, Jr.)							PL 2 Past, present and future of geriatric oncology (Hans Wildiers)				
12:00	LS 1 Roche Breast Cancer			LS 2 MSD Lung Cancer					Noe Kyeong Kim Memorial Award & Lecture				
	Break								LS 3 AstraZeneca NSCLC	SL 11 Sanofi-Aventis Korea: CRC			
13:00	SP 1 Research, Write, Publish	OP 1	ES 1 Immuno-oncologic therapy and pharmacologic management		OP 2	OP 3		Break					
14:00	Break								PL 3 The reality versus potential of immune check-point inhibitors as cancer therapeutics (Heather A. Wakelee)				
15:00	JS 1 Utilization of NGS to improve patient care	SS 5 Modulating microenviron- ment for cancer treatment	JS 2 The promise of combining RT and immunotherapy		ES 2 Oncology nursing care in immune -oncology and targeted agent			JS 5 Clinical trials in Asia: Opportunities and challenges	SS 10 Geriatric Oncology	JS 6 Evolving strategies for surgery and systemic therapy in the neoadjuvant treatment era	OP 5		
16:00	Break								Break				
17:00	JS 3 Integrated platform for precision medicine	SS 6 Translational Research-Biomarker studies to achieve desired clinical applications	SS 7 GY cancer multimodality treatment		SP 2 The current state and system of global drug accessibility			JS 7 Immune Biomarker	SS 11 Radiomics: Primer for medical oncologists	SP 3 Discrepancy between clinical practice and regulation in Korea	ES 3 CRC/CRA in clinical trial of precision medicine		
18:00	SL 1 Boryung Pharmaceutical: Pancreatic Cancer	SL 2 Pfizer Ltd.: Breast Cancer	SL 3 Novartis Korea: Rare Lung Cancer	SL 4 Lilly Korea: Stomach Cancer	SL 5 Menarini Korea: Palliative Medicine		SL 6 ONO Pharma Korea: Immune -oncology	Closing Ceremony					
18:30													

AWARDS



Best Oral
USD 1,000



Best Poster
USD 300

* Session Abbreviation

- PL : Plenary Lecture
- SP : Special Symposium
- SS : Scientific Symposium
- JS : Joint Symposium
- ES : Multidisciplinary Oncology
Team Education Session
- LS : Luncheon Symposium
- SL : Satellite Symposium
- OP : Oral Presentation

KSMO 2019 Secretariat

3F, MS B/D, 12, Eonju-ro 79-gil,
Gangnam-gu, Seoul, Korea
Tel: +82-2-557-8422
Fax: +82-2-557-8428
E-mail: info@ksmo2019.org